Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Dimension Therapeutics, Inc. (DMTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/07/2017 GN Ultragenyx Completes Tender Offer and Acquisition of Dimension Therapeutics
10/31/2017 GN SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Files Class Action Suit Against Dimension Therapeutics, Inc.
10/26/2017 GN Ultragenyx and Dimension Announce Expiration of Hart-Scott-Rodino Waiting Period for Ultragenyx's Acquisition of Dimension
10/02/2017 GN Ultragenyx Comments on Dimension Therapeutics' Announcement that Ultragenyx's Offer is a “Superior Proposal” 
10/02/2017 GN REGENXBIO Responds to Notification of a Superior Proposal Under Its Merger Agreement With Dimension Therapeutics
09/19/2017 GN Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a “Superior Proposal”
09/18/2017 GN Dimension Confirms Receipt of Unsolicited Proposal from Ultragenyx
09/18/2017 GN Ultragenyx Proposes to Acquire Dimension Therapeutics for $5.50 Per Share in Cash
08/31/2017 GN Dimension Therapeutics Commences Patient Dosing in Global, Multi-Center Phase 1/2 Clinical Trial of DTX301 in Ornithine Transcarbamylase (OTC) Deficiency
08/25/2017 GN REGENXBIO to Acquire Dimension Therapeutics
07/13/2017 GN Women In Bio Announces Mary Thistle Joins Enterome's Board of Directors
06/27/2017 GN Dimension Therapeutics Completes Strategic Review and Updates Corporate Priorities
05/10/2017 GN Dimension Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
04/24/2017 GN Dimension Therapeutics Announces Presentations at the Upcoming American Society for Gene and Cell Therapy (ASGCT) Annual Meeting
03/09/2017 GN Dimension Therapeutics Announces Full Year 2016 Financial Results and Recent Updates Across Rare and Metabolic Disease Portfolio and in HeLa Manufacturing
02/07/2017 GN Dimension Therapeutics Elects Dr. John A. Hohneker to Its Board of Directors
01/31/2017 GN Dimension Announces Interim Topline Results from Ongoing Phase 1/2 Clinical Program for DTX101, Dimension's Lead AAV Product Candidate in Development for Adult Patients with Moderate/Severe to Severe Hemophilia B

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy